September 23, 2017 7:09 PM ET

Pharmaceuticals

Company Overview of Huvepharma AD

Company Overview

Huvepharma AD, a pharmaceutical company, develops, manufactures, and markets human and animal health products. Its products include anticoccidials, veterinary products, feed additives, APIs, and medicated feed additives. The company also manufactures and markets enzymes for food, feed, and industrial applications. It offers its products through distributors and representatives in Europe, the United States, Canada, and internationally. Huvepharma AD was founded in 1954 and is based in Sofia, Bulgaria. It has offices and subsidiaries in Bulgaria, Belgium, Poland, China, Taiwan, Thailand, the United States, the Russian Federation, India, and Brazil. Huvepharma AD operates as a subsidiary of Adv...

5th floor

3a Nikolay Haytov Str.

Sofia,  1113

Bulgaria

Founded in 1954

Phone:

359 2 862 53 31

Fax:

359 2 862 53 34

Key Executives for Huvepharma AD

Director of Technical Services
Director of Technical Services-Poultry
Compensation as of Fiscal Year 2017.

Huvepharma AD Key Developments

Huvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme

Huvepharma EOOD and Intrexon Corporation announced they have entered into a research collaboration agreement. The collaboration represents the first commercial application of Intrexon's proprietary fungal expression platform to produce a new animal feed enzyme developed by Huvepharma. Utilizing economical fermentation processes, fungal systems are an ideal production platform for enzymes and other feed additives given their high protein yield and substantial secretion capacity. Through the collaboration, Intrexon plans to engineer optimized cell lines to produce the target feed enzyme, and Huvepharma will test their applicability in large-scale production of feed additives. Based on the results of the program, the companies intend to pursue fermentative production of the target enzyme as well as look for additional commercial opportunities utilizing this platform.

Huvepharma to Invest EUR 150 Million in New Plant

Huvepharma reported that it will invest EUR 150 million in a new manufacturing facility in the town of Peshtera, in southwestern Bulgaria. Upon completion, the facility will increase by 50% the company's production of animal food supplements and health products. Huvepharma also announced it intends to introduce several new products in the next few years.

Similar Private Companies By Industry

Company Name Region
Commercial League Healthcare Group Inc. Europe
Correct Farm EOOD Europe
Elpharma AD Europe
Fortex Nutraceuticals OOD Europe
Mayfair Group plc AD Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 21, 2016
Biovet Joint Stock Company
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Huvepharma AD, please visit www.huvepharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.